Vyaire Medical Acquires Revolutionary Medical Devices, Inc

[junkie-button url=”https://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

[junkie-alert style=”red”] Vyaire Medical, Inc., the healthcare industry’s dedicated “breathing company,” today announced it has acquired Revolutionary Medical Devices, Inc. (RMD), of Tucson, Ariz., a maker of innovative products for airway management, focused on significantly improving patient outcomes. [/junkie-alert]

RMD’s main product, the SuperNO2VA™ is a complete noninvasive nasal PAP ventilation system designed for use in the treatment of respiratory insufficiency from collapse of the airway during or after sedation, or during the intubation process. The SuperNO2VA system effectively opens the upper airway, maintains patency, and allows the anesthesiologist to effectively ventilate the patient. It is designed to reduce the likelihood of respiratory compromise via perioperative hypoxemia, particularly with “high risk” patients who may present with difficult airways.

“The acquisition of Revolutionary Medical Devices allows Vyaire to bring another clinically-differentiated airway management solution to the medical device marketplace,” said Dave Mowry, Vyaire’s President and Chief Executive Officer. “RMD’s SuperNO2VA nasal PAP ventilation system enables anesthesiologists to provide oxygen to sedated patients in a more controlled and noninvasive way, and is exactly the type of unique and thoughtfully-designed product we want to bring to our customers.”

The SuperNO2VA system can also be used to pre-oxygenate, relieve UAO, maintain ventilation, and rescue ventilate, as well as for intra-oral procedures. It can also be used peri-operatively. The system, which functions with an air-tight mask over the patient’s nose, allows for the use of positive pressure within the mask to help maintain an open airway that allows for continuous nasal oxygenation and ventilation throughout sedation.

Vyaire management sees the acquisition of RMD as another step toward the company’s stated goal of becoming the global leader in the respiratory care market.

Terms of the transaction were not disclosed.